Sudo Biosciences is a biopharmaceutical company committed to designing and developing novel, best-in-class medicines to transform patients’ lives. Our lead programs target the tyrosine kinase 2 (TYK2) pseudokinase domain. TYK2 is a key mediator in cytokine signaling pathways that have been linked to a broad range of immune-mediated inflammatory conditions.

Frazier Life Sciences

Velosity Capital

Sanofi Ventures

50 South Capital

Monograph Capital

Enavate Sciences

Eventide

Surveyor Capital

Sudo Biosciences

Sudo Biosciences lands additional $30m for TYK2 inhibitors with potential in Alzheimer’s

Dementia Discovery Fund (DDF) joins new investors, citing Sudo’s potential in multiple neuroinflammatory diseases, including Alzheimer’s.

#longevity #investment #Alzheimers

Improving care for patients living with debilitating neuroinflammatory and autoimmune conditions. 💊🌟 
We're thrilled to announce our investment in Sudo Biosciences. The company is developing best-in-class precision TYK2 inhibitors, potential game-changers in treating immune-mediated #inflammatory conditions and #neurodegenerative diseases. 

This investment will support Sudo Biosciences in advancing two precision TYK2 inhibitors into the clinic for neuroinflammatory and autoimmune conditions including #multiplesclerosis, #ALS, and #psoriasis.
Read more: https://bwnews.pr/498nmea

Excited to announce we have completed a second close of its Series B financing, raising an additional $30 million from new investors Dementia Discovery Fund (DDF)  (DDF, a SV Health Investors Fund), Leaps by Bayer, and UPMC Enterprises the innovation, commercialization and venture capital arm of UPMC. This brings the total raised in this upsized round to $147 million.

“We are pleased to welcome these new investors as they each offer unique strategic value which will be meaningful for Sudo as we advance our precision TYK2 inhibitors into the clinic,” said Scott Byrd, Chief Executive Officer, Sudo Biosciences. “This further funding enhances our ability to optimize the development of our pipeline programs.”

Read the release:

https://lnkd.in/ed_5677K

We had an excellent crowd on hand to hear our very own Mike Bolinder, Scott Byrd, CEO of Sudo Biosciences, and Derek A Small, founder of Luson Bioventures, speaking at the #JP2024 in San Francisco. 

Special thanks to the Indiana Economic Development Corporation, Elevate Ventures, and Barnes & Thornburg LLP for partnering with BioCrossroads and giving us this incredible opportunity to showcase Indiana as a #lifesciences powerhouse.  

Thanks Nasdaq for celebrating our recent $116M Series B funding round in Times Square today! 

Exciting start to kick off 2024, and looking forward to seeing everyone at #JPM24 next week. 

Sharing our Series B press release: 

https://lnkd.in/edgkg4dg 

#TYK2 #biotech #funding 

DNSSEC

U.S. Server Location

CrUX Dataset

CrUX Top 50m

Chief Development Officer (CDO)

Gordon McMurray

Director of Finance

Rachel Garrett

Executive Assistant/Office Manager

Fenella Smith

Head of Translational Pharmacology

Rachel Eccles

Shinichiro Fuse

Edd Fleming

Christopher Gagliardi

Scott Byrd

Imran Babar

Chief Business Officer

Anjali Pandey

SVP, Medicinal Chemistry

Daniel Estes

Founder & Director

Great Lakes Companies With Fewer Than 50 Employees (Top 10K)

Great Lakes Early Stage Companies With Less Than $500M in Revenue

Midwestern US Companies With Less Than $1B in Revenue (Top 10K)

Life Science Early Stage Companies With More Than 10 Employees

Sudo Biosciences is a biopharmaceutical company that designs and develops medicines that target the tyrosine kinase 2 (TYK2) pseudokinase domain, a crucial mediator in cytokine signaling pathways that have been linked to a broad range of immune-mediated inflammatory conditions. Its pipeline of next-generation TYK2 inhibitors includes a potential brain-penetrant candidate for treating multiple sclerosis and neurodegenerative diseases with underlying neuroinflammation and a potential topical candidate for immune-mediated dermatologic diseases. It helps patients receive the cure or the treatment of multiple sclerosis and neurodegenerative diseases with underlying neuroinflammation at a competitive cost.

Series B - Sudo Biosciences

Series A - Sudo Biosciences

Carmel

Indiana

United States

North America

Sudo Biosciences on LinkedIn: We are very pleased to announce another important addition to the Sudo…

Sudo Biosciences on LinkedIn: We are excited to announce a few new members of the Sudo Biosciences…

Sudo Biosciences on LinkedIn: We are pleased to announce expanded responsibilities for Imran B. and…

Sudo Biosciences on LinkedIn: We are pleased to announce expanded responsibilities for Imran B. and… | 28 comments

Sudo Biosciences’ Post

Jennifer Jones on LinkedIn: Sudo Biosciences | Targeting Tyrosine kinase 2 | TYK2 therapeutics

Sudo Biosciences presents new TYK2 inhibitors

Sudo Biosciences Announces Second Close of Upsized Series B Financing Bringing Total Raised in Round to $147M

A TYK2 inhibitor designed to penetrate the brain, targeting multiple sclerosis and neurodegenerative diseases.

A topical formulation of a TYK2 inhibitor for treating psoriasis and other immune-mediated dermatologic conditions.

Philippines

Asia

Indonesia

C4 Therapeutics is a biotechnology company focused on developing targeted protein degradation therapeutics.

C4 Therapeutics

Kuano is a company specializing in targeted protein degradation with a focus on innovative research and development.

Kuano

Avilar Therapeutics is engaged in the development of targeted protein degradation therapies for various diseases.

Avilar Therapeutics

Sudobio is a biotechnology company focused on developing next-generation protein degradation therapeutics for the treatment of diseases with high unmet medical needs.

news impact assignment basic	general	May 7, 2024 10:42 PM	20f68c1b
public peers	general	May 7, 2024 10:42 PM	99824b3c
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	May 7, 2024 10:42 PM	3562697a
company summary	general
signals	general
crunchbase trigger	general	Dec 4, 2024 8:54 AM	f8d3afb7
crunchbase profile	general	Dec 4, 2024 12:36 PM	e8d1467a
li profile	general	May 7, 2024 10:42 PM	65157199
translate crunchbase fundingrounds	general	Dec 4, 2024 1:37 PM	dec7dc1a
peers	general
news basic	general	May 7, 2024 10:42 PM	0fb5ec1a
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:SUDOBIO

Sudobio